Tower Research Capital (TRC)’s Alexza Pharmaceuticals Inc ALXA Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALXA Stock Details ALXA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,068	Closed	–	–	5617
2015 Q4	$0	Buy	1,068 +153	+17%	+$158	﹤0.01%	5565
2015 Q3	$1K	Buy	+915	New	+$1.07K	﹤0.01%	3825
2015 Q2	–	Sell	-227	Closed	–	–	5519
2015 Q1	$0	Sell	227 -77	-25%	-$158	﹤0.01%	5360
2014 Q4	$0	Sell	304 -578	-66%	-$1.03K	﹤0.01%	5259
2014 Q3	$2K	Sell	882 -327	-27%	-$1.25K	﹤0.01%	3975
2014 Q2	$6K	Buy	1,209 +595	+97%	+$2.57K	﹤0.01%	2788
2014 Q1	$3K	Buy	614 +28	+5%	+$144	﹤0.01%	3751
2013 Q4	$3K	Sell	586 -301	-34%	-$1.48K	﹤0.01%	3926
2013 Q3	$4K	Buy	887 +864	+3,757%	+$4.07K	﹤0.01%	3872
2013 Q2	$0	Buy	+23	New	+$104	﹤0.01%	4026

Other funds holding ALXA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CLOS

Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tower Research Capital (TRC)'s ALXA Position: Q1 2016 in Review

Tower Research Capital (TRC) sold out of Alexza Pharmaceuticals Inc (ALXA) in Q1 2016, closing a stake of 1,068 shares.

Tower Research Capital (TRC) first reported a position in ALXA in Q2 2013 and held it in 10 quarters. The position peaked at $6K in Q2 2014. 25 funds tracked by Wall St. Rank hold ALXA as of Q1 2016.

Tower Research Capital (TRC) reported no remaining Alexza Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 1,068 Alexza Pharmaceuticals Inc shares in Q1 2016.
Tower Research Capital (TRC) first reported a position in Alexza Pharmaceuticals Inc in Q2 2013 and held it in 10 quarters.
Tower Research Capital (TRC)'s Alexza Pharmaceuticals Inc position peaked at $6K in Q2 2014.
25 funds tracked by Wall St. Rank held Alexza Pharmaceuticals Inc as of Q1 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2016, filed 16 May 2016.